{"id":51683,"date":"2025-12-24T07:29:04","date_gmt":"2025-12-24T06:29:04","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment\/"},"modified":"2025-12-24T07:29:04","modified_gmt":"2025-12-24T06:29:04","slug":"mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment\/","title":{"rendered":"Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment"},"content":{"rendered":"<div>\n<p><b>Curr Opin Immunol<\/b>. 2025 Dec 22;98:102712. doi: 10.1016\/j.coi.2025.102712. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Sj\u00f6gren&#8217;s disease (SjD) is a chronic autoimmune disorder in which sustained B-cell activation drives glandular injury and systemic complications. Epithelial stress and interferon tone amplify B-cell activating factor (BAFF)-dependent survival, skewing selection toward autoreactive clones in both glands and blood. In addition, single-cell B-cell receptor analyses have uncovered interferon-high endotypes with tissue-imprinted oligoclonality and biased isotype and light-chain usage. Within salivary glands, ectopic germinal centers and FcRL4\u207a B cells act as local &#8216;training sites,&#8217; integrating Tfh\/Tph help, CXCL13 cues, and BAFF\/APRIL-NF-\u03baB signaling to sustain plasmablast differentiation. Extrafollicular trajectories &#8211; double-negative and age-associated B cells &#8211; expand in IFN\/TLR7 and IL-21 milieus, while regulatory B-cell restraint is diminished. Emerging data also implicate glycolysis and mTORC1-GLUT1 metabolism in sustaining B-cell hyperactivation. Chronic B-cell receptor signaling and clonal evolution provide a bridge to lymphoma risk. In this review, we outline how these converging pathways define molecular endotypes and propose a precision framework linking them to targeted therapy in SjD.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41435726\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8900118&amp;ff=20251224012904&amp;v=2.18.0.post22+67771e2\">41435726<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.coi.2025.102712\">10.1016\/j.coi.2025.102712<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Curr Opin Immunol. 2025 Dec 22;98:102712. doi: 10.1016\/j.coi.2025.102712. Online ahead of print. ABSTRACT Sj\u00f6gren&#8217;s disease (SjD) is a chronic autoimmune disorder in which sustained B-cell activation drives glandular injury and systemic complications. Epithelial stress and interferon tone amplify B-cell activating factor (BAFF)-dependent survival, skewing selection toward autoreactive clones in both glands and blood. In addition, &#8230; <a title=\"Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/24\/mapping-the-b-cell-axis-in-sjogrens-disease-repertoire-microenvironment-and-potential-routes-to-precision-treatment\/\" aria-label=\"Read more about Mapping the B-cell axis in Sj\u00f6gren&#8217;s disease: repertoire, microenvironment, and potential routes to precision treatment\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59,42],"tags":[],"class_list":["post-51683","post","type-post","status-publish","format-standard","hentry","category-current-opinion-in-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/51683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=51683"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/51683\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=51683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=51683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=51683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}